4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual MeetingGlobeNewsWire • 09/24/21
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational HighlightsGlobeNewsWire • 08/12/21
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and LicenseGlobeNewsWire • 06/24/21
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational HighlightsGlobeNewsWire • 05/13/21
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DMEGlobeNewsWire • 05/12/21
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution PlatformGlobeNewsWire • 05/04/21
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care ConferenceGlobeNewsWire • 04/30/21
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate StudiesGlobeNewsWire • 04/27/21
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational HighlightsGlobeNewsWire • 03/25/21
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry DiseaseGlobeNewsWire • 03/09/21